Humana AB shares surged on heavy buying after Ambea AB unveiled a recommended public takeover offer that values the combined transaction at roughly SEK 2,960 million. The offer, announced early in the trading session, consists of SEK 20 in cash together with 0.305 newly issued Ambea shares for each Humana share, a package that immediately pushed Humana's stock sharply higher.
Investors reacted strongly: Humana climbed +24.3% to SEK 61.10 on the day, and intraday the stock reached a fresh 52-week high of SEK 61.60. That intraday peak exceeded the prior 52-week high of SEK 53.40, illustrating the market's rapid re-pricing of the company's prospects following the bid.
The takeover proposal entered the market with notable early support. Shareholders holding approximately 41.9% of Humana's outstanding shares - including the company's largest investor Impilo, and other significant holders Incentive and Per Granath - have conditionally committed to accepting the offer. In addition, Humana's board of directors has formally recommended that remaining shareholders accept the proposal, a development that market participants interpreted as reducing a major element of deal risk.
Ambea has outlined expected cost benefits from the combination. Management projects annual pre-tax cost synergies of around SEK 120 million at full run-rate, with those efficiencies expected to materialize in the second year following completion of the transaction. Ambea also expects the deal to be immediately accretive to its adjusted earnings per share in the first full fiscal year after closing.
Market context was largely neutral to constructive. The broader Swedish equity market provided a calm backdrop, with the OMX Stockholm 30 having been broadly positive in recent weeks. U.S. benchmarks - the S&P 500, Dow Jones, and NASDAQ - were essentially flat on the trading day, underscoring that Humana's dramatic move was driven by the company-specific M&A announcement rather than broader macro factors.
Humana had been scheduled to report standalone earnings next on July 17, 2026, but the takeover bid has become the dominant near-term event for the stock, overshadowing that forthcoming report. The combination of a meaningful acquisition premium embedded in the offer, the board's recommendation, and pre-committed acceptances amounting to nearly half the share register created a powerful, self-reinforcing catalyst for the share price.
With investors bidding the stock to new highs and the market clearly pricing a high probability that the Ambea transaction will complete, the takeover announcement emerged as the defining development for Humana shares on the trading day.